Group 1 - The company Pianzaihuang (600436.SH) plans to invest in the CICC (Zhangzhou) Medical Industry Investment Partnership (Limited Partnership), tentatively named "CICC Medical Fund" [1] - The company's wholly-owned subsidiary, Zhangzhou Pianzaihuang Investment Management Co., Ltd., will act as a limited partner and contribute 200 million yuan, accounting for 20% of the fund's target fundraising scale [1] - The main investment areas of the fund will focus on the healthcare sector, including traditional Chinese medicine, biomedicine, medical devices, medical services, daily chemical beauty products, and health and wellness industries [1]

证券代码：600436 证券简称：片仔癀 公告编号：2025-032 漳州片仔癀药业股份有限公司 关于公司董事、高级管理人员变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、关于董事、高级管理人员变动的基本情况 杨海鹏先生在担任公司董事、总会计师期间，恪尽职守、忠诚履 特此公告。 漳州片仔癀药业股份有限公司 1 / 2 职，勤勉尽责、兢兢业业，以良好专业的素养和创新的理念，有力推 动了公司的规范运作、财务管理及健康发展，作出了重要贡献。在此， 公司及董事会对杨海鹏先生的付出表示衷心感谢！ 三、董事会审计委员会意见 为确保公司财务管理工作的正常开展，在公司未正式聘任新的总 会计师期间，经公司董事会审计委员会审议，同意指定副总经理何炜 先生代行总会计师职责。 漳州片仔癀药业股份有限公司（以下简称"公司"）董事会于近 日收到董事、总会计师杨海鹏先生提交的书面辞职报告。杨海鹏先生 因工作调整原因，辞去公司董事及总会计师等职务。辞职后，杨海鹏 先生仍担任顾问职务。具体情况如下： | 董事、 杨海鹏 总会计师 | 职务 | ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-033 漳州片仔癀药业股份有限公司 关于投资参与中金医疗基金暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟投资标的名称：中金（漳州）医疗产业投资合伙企业（有限 合伙）（暂定名，以市场监督管理部门核准为准；以下简称"中金医 疗基金"）。 拟投资领域：本基金的主要投资领域为医疗大健康投资方向， 主要投资于中医药、生物医药、医疗器械、医疗服务、日化美妆和康 养大健康等相关产业，包括但不限于片仔癀产业链项目、片仔癀产业 园以及招商引资落地漳州的项目。 拟投资金额：漳州片仔癀药业股份有限公司（以下简称"公司"） 全资子公司漳州片仔癀投资管理有限公司（以下简称"片仔癀投资"） 拟作为有限合伙人以自有或自筹资金认缴出资人民币 20,000 万元， 占中金医疗基金目标募集规模的比例为 20%。 本次对外投资系与关联方漳州片仔癀资产经营有限公司（以下 简称"资产经营"）、漳州市旅游投资集团有限公司（以下简称"旅 投集团"）共同投资，构成关联交易， ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-034 漳州片仔癀药业股份有限公司 第七届监事会第二十四次会议决议公告 1 / 2 金暨关联交易的公告》（2025-033 号）。 本议案无需提交至公司股东大会审议。 特此公告。 漳州片仔癀药业股份有限公司 监 事 会 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）第七届监事 会第二十四次会议于 2025 年 9 月 28 日（星期日）上午 11：00 在公 司片仔癀大厦 21 楼会议室以通讯会议方式召开。会议通知和议案以 专人送达、电子邮件方式发出。本次会议应参加表决的监事 3 名，实 际表决的监事 3 名。会议召开符合《公司法》和《漳州片仔癀药业股 份有限公司章程》（以下简称"《公司章程》"）的有关规定，合法、 有效。本次会议由监事会主席许式彬先生主持，议案经与会监事审议， 做出如下决议： 一、审议通过《公司关于全资子公司与专业投资机构共同投资设 立中金医疗基金暨关联交易的议案》； 监事会认为：公司本次与中金资本运 ...

Group 1 - The company plans to invest in the CICC (Zhangzhou) Medical Industry Investment Partnership (tentative name), referred to as "CICC Medical Fund" [1] - The company's wholly-owned subsidiary, Zhangzhou Pianzaihuang Investment Management Co., Ltd., will act as a limited partner and contribute 200 million yuan, accounting for 20% of the target fundraising scale of the CICC Medical Fund [1] - The main investment areas of the fund include healthcare investments, focusing on traditional Chinese medicine, biomedicine, medical devices, medical services, daily chemical beauty products, and health and wellness industries [1] Group 2 - The fund will invest in projects related to the Pianzaihuang industry chain, Pianzaihuang industrial park, and projects that attract investment to Zhangzhou [1]

截至发稿，片仔癀市值为1190亿元。 每经头条（nbdtoutiao）——去美国的"打工人"天塌了！特朗普10万美元签证费击碎"美国梦"，美企加 速外包，加拿大趁机"抢人" （记者 王晓波） 每经AI快讯，片仔癀（SH 600436，收盘价：197.26元）9月28日晚间发布公告称，杨海鹏先生因工作调 整原因，辞去公司董事及总会计师等职务。辞职后，杨海鹏先生仍担任顾问职务。 2025年1至6月份，片仔癀的营业收入构成为：医药制造业占比55.5%，医药流通业占比36.76%，化妆品 和护肤品占比5.95%，其他占比1.53%，其他业务占比0.25%。 ...

Group 1 - The company plans to invest in the CICC (Zhangzhou) Medical Industry Investment Partnership (tentative name, referred to as "CICC Medical Fund") [1] - The company's wholly-owned subsidiary, Zhangzhou Pianzaihuang Investment Management Co., Ltd., will act as a limited partner and contribute 200 million yuan, accounting for 20% of the target fundraising scale of the CICC Medical Fund [1] - The main investment areas of the fund include healthcare investments, focusing on traditional Chinese medicine, biomedicine, medical devices, medical services, daily chemical beauty products, and health and wellness industries [1]

Core Insights - The "2025 Hong Kong International Traditional Chinese Medicine Conference" was held in Hong Kong, focusing on promoting high-quality TCM globally, attracting nearly 500 experts and representatives from various regions [1] - The conference received strong support from the National Administration of Traditional Chinese Medicine and the Hong Kong government, aiming to build a high-end platform for collaboration and cultural exchange in the TCM industry [2] - Pianzaihuang Company showcased its core products at the conference, highlighting its efforts in modernizing and internationalizing traditional Chinese medicine [1][5] Group 1: Industry Development - The conference emphasized the importance of collaboration in the TCM industry, launching the "High-Quality Development of the Traditional Chinese Medicine Industry Chain" initiative, with Pianzaihuang Company as a key signatory [2] - Pianzaihuang is recognized as a leading brand in the TCM sector, consistently ranking among the top exporters of Chinese patent medicines [3] Group 2: Product Showcase - Pianzaihuang's exhibition featured a range of traditional Chinese medicines and health products, attracting significant attention from industry experts and media, enhancing its brand recognition in the Greater Bay Area and international markets [4] - The company received positive feedback for its commitment to preserving traditional techniques while promoting technological innovation in its products [4] Group 3: Strategic Goals - The participation in the conference is part of Pianzaihuang's strategy to accelerate the internationalization of TCM and expand its global influence [5] - The company aims to leverage Hong Kong's unique position as a cultural bridge to enhance its international partnerships and explore overseas opportunities [5]

Investment Rating - The report does not explicitly provide an investment rating for the beauty industry Core Insights - The beauty industry is experiencing a significant transformation driven by consumer preferences for high-quality, effective products and the integration of technology in skincare and cosmetics [4][6][10] Industry Trends - The high-end fragrance segment is witnessing robust growth, with the Chinese perfume market projected to reach 24.9 billion yuan by 2025 and exceed 33.9 billion yuan by 2028, reflecting a compound annual growth rate of 8% [4] - Domestic beauty brands are focusing on scientific innovation, market segmentation, and globalization to enhance competitiveness [6][7] - The integration of medical aesthetics and beauty is becoming a trend, with a projected annual growth rate of 10%-15% for the medical aesthetics market from 2024 to 2027 [10] - The beauty market is seeing a shift towards multi-brand strategies, with companies like Proya and Shiseido leading the way [6][11] Market Environment - Douyin e-commerce is revitalizing the perception of "Chinese good ingredients," enhancing consumer trust in domestic skincare products through educational campaigns [4] - The domestic beauty market grew by 3.1% in the first half of 2025, with significant performance disparities among companies [6] - The trend of "reverse export" to South Korea is emerging, as domestic brands seek to penetrate the Korean market through differentiated product offerings [6] Top Brand Dynamics - Proya leads the domestic beauty market with a revenue of 5.36 billion yuan, followed closely by other major players [11] - The report highlights the rise of makeup artist brands, with Unilever investing in Hung Vanngo Beauty, indicating a growing interest in professional makeup lines [13] - L'Oréal is accelerating its presence in the fragrance market with the launch of high-end perfumes, reflecting a strategic shift towards premium products [14] - The beauty industry is witnessing a surge in e-commerce, with platforms like JD.com reporting double-digit growth in beauty sales [18]

Core Insights - The 2025 China Fragrance, Flavor, and Cosmetics Industry Annual Conference and Boutique Expo was held from September 25 to 27 in Nanjing, showcasing the innovation strength of the Chinese cosmetics industry [1] - Pizhou Pharmaceutical's cosmetics division presented its key products, including the Snow Skin Whitening series and the Golden Line Lotus Repair series, emphasizing technological innovation in traditional herbal ingredients [1][2] Company Highlights - Pizhou Pharmaceutical has established a comprehensive research system integrating production, learning, research, medicine, and testing, with five major research centers focused on Chinese ingredient innovation [1] - The company holds 34 special certificates for spot removal and whitening, demonstrating its commitment to research and development over 45 years [1] - The Snow Skin Whitening series, developed over ten years, utilizes Chinese ingredients to achieve healthy and fair skin through a coordinated approach with scientific components [2] - The Golden Line Lotus Repair series focuses on sensitive skin barrier repair, utilizing self-researched lotus extract and a standardized planting base in Zhangzhou [2] - The company employs modern extraction technologies to enhance the efficacy of traditional ingredients, such as using supercritical CO2 extraction for ginseng [2] Industry Trends - The event highlighted a shift in the industry from traffic competition to a dual-driven value competition model of "technology + brand" [2] - Pizhou Pharmaceutical is recognized as a "Golden Partner" by the China Fragrance and Cosmetics Association, indicating its growing influence and competitive edge in the market [2]